Fig. 1
From: Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Aβ isoforms levels discriminate tau pathology positivity (T+) and neurodegeneration positivity (N+) in CU individuals. A T+ defined as CSF p-tau > 19.2 pg/mL. B N+ defined as CSF t-tau > 242 pg/mL. C Aβ1−38, D Aβ1−40 and E Aβ1−42 levels for T− and T+ individuals. F Aβ1−42/Aβ1−40, G Aβ1−42/Aβ1−38 and H Aβ1−40/Aβ1−38 ratios for T− and T+ individuals. I Aβ1−38, J Aβ1−40 and K Aβ1−42 levels for N− and N+ individuals. L Aβ1−42/Aβ1−40, M Aβ1−42/Aβ1−38 and N Aβ1−40/Aβ1−38 ratios for N− and N+ individuals. Boxplots are displayed as median (center line) and extend from the 25th to 75th percentiles. The whiskers go down to the smallest value and up to the largest. Statistical differences were tested using Mann-Whitney test (*p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001)